Skip to main content

Dr. Ramesh K. Moolani, M.D.

Hematology & Oncology (Hematology & Oncology Physician)

855 3rd Ave Ste 3330
Chula Vista, CA 91911

Who else practices at this address →

San Diego County includes primary care (1% of residents) and mental health (1% of residents) shortage areas. About shortage areas

Call (619) 745-1031

  • Medicare participating

At a glance

Years since graduation
25
In the NPI registry since
2007
Medicare patients seen, 2024
279

Licensed in California since 2017, according to the Medical Board of California. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2007Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    CA license C149851 (first issued 2017; current) · MI license 4301083830
  • Internal Medicine Physician
    MI license 4301083830

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
279
Services billed
133,124
Patients’ average age
75
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, fosaprepitant, 1 mg6,45012
Injection, denosumab, 1 mg5,04011
Injection, dexamethasone sodium phosphate, 1 mg1,41224
Injection, palonosetron hcl, 25 mcg81120
Insertion of needle into vein for collection of blood sample755231
Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg46813
Administration of chemotherapy into vein, 1 hour or less26043
Established patient office or other outpatient visit, 30-39 minutes21879
Injection of drug or substance under skin or into muscle21136
Injection, zoledronic acid, 1 mg19816

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 44 companies reported 185 payments worth $5,111 in total to this clinician.

By type
Food and Beverage$3,931
Long term medical supply or device loan$1,000
Education$181

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Dec 1, 2025Janssen Biotech, Inc.
Dec 1, 2025
Education
DARZALEX; TALVEY; TECVAYLI · Oncology · in-kind
$99.99
Jan 23, 2025Novartis Pharmaceuticals Corporation
Jan 23, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Feb 21, 2025Novartis Pharmaceuticals Corporation
Feb 21, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Mar 26, 2025Novartis Pharmaceuticals Corporation
Mar 26, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
May 15, 2025Novartis Pharmaceuticals Corporation
May 15, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Apr 24, 2025Novartis Pharmaceuticals Corporation
Apr 24, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Jun 12, 2025Novartis Pharmaceuticals Corporation
Jun 12, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Jul 25, 2025Novartis Pharmaceuticals Corporation
Jul 25, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Aug 21, 2025Novartis Pharmaceuticals Corporation
Aug 21, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Oct 23, 2025Novartis Pharmaceuticals Corporation
Oct 23, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
All 15 payments other than meals, newest first
All payments other than meals
DateCompanyWhat it was forAmount
Dec 30, 2025Novartis Pharmaceuticals Corporation
Dec 30, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Dec 2, 2025Gilead Sciences, Inc.
Dec 2, 2025
Education
Trodelvy · ONC · in-kind
Company’s description;4221936;G360;10027379
$12.42
Dec 1, 2025Janssen Biotech, Inc.
Dec 1, 2025
Education
DARZALEX; TALVEY; TECVAYLI · Oncology · in-kind
$99.99
Nov 26, 2025Novartis Pharmaceuticals Corporation
Nov 26, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Oct 23, 2025Novartis Pharmaceuticals Corporation
Oct 23, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Oct 22, 2025Agios Pharmaceuticals, Inc.
Oct 22, 2025
Education
PYRUKYND · Genetically Defined Disease · in-kind
$68.10
Sep 19, 2025Novartis Pharmaceuticals Corporation
Sep 19, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Aug 21, 2025Novartis Pharmaceuticals Corporation
Aug 21, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Jul 25, 2025Novartis Pharmaceuticals Corporation
Jul 25, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Jun 12, 2025Novartis Pharmaceuticals Corporation
Jun 12, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
May 15, 2025Novartis Pharmaceuticals Corporation
May 15, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Apr 24, 2025Novartis Pharmaceuticals Corporation
Apr 24, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Mar 26, 2025Novartis Pharmaceuticals Corporation
Mar 26, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Feb 21, 2025Novartis Pharmaceuticals Corporation
Feb 21, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33
Jan 23, 2025Novartis Pharmaceuticals Corporation
Jan 23, 2025
Long term medical supply or device loan
KISQALI · Oncology · in-kind
$83.33

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in California →

Other Hematology & Oncology clinicians in Chula Vista

Sources

NPI registry (CMS NPPES, November 2026; record last updated June 7, 2022), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1437272010. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.